Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Savara Inc (SVRA)
A forensic read on Savara Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-4.8
Altman Z-score
Clean
Earnings quality
4
Forensic signals
-87.2%
ROE
$1.2B
Market cap
Savara Inc earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -4.8, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-49%Return on invested capital.Return on invested capital is -49% and slipping from -38% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+15.2%/yrShare-count dilution.Diluted share count changed +46% over the last 3 years to FY2025 (+15.2%/yr). The count is GROWING — existing holders are being diluted. That's ~15.2% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~46%.
1987% of revStock-based comp load.Stock-based compensation ran 1987% of revenue in FY2020. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
$27MGoodwill impairments.Took $27M of goodwill writedowns across 1 year(s) (FY2019 ($27M)). Writedowns mean past acquisitions underperformed what was paid for them — worth weighing on capital-allocation skill.
Key fundamentals
Net Margin-19305.4%
Debt / Equity0.15x
Free Cash Flow$-101.1M
Latest Revenue257000.00
Return on Equity-58.5%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Savara Inc:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about SVRA's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown